AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 526268: 1,3,4,8,9-Pentabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,2,6,7,9-pentabromodibenzofuran. Molecular Formula: C12H3Br5O. Molecular Weight: 562.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NNDSS - TABLE 1L. Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection to Giardiasis

NNDSS - Table 1L. Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection to Giardiasis - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html 

Footnotes: 
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
2010 State Profile — Arkansas

This state profile includes data from facilities in Arkansas that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Arkansas. In Arkansas, 62 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 3,936 clients in substance abuse treatment on March 31, 2010. The survey response rate in Arkansas was 98.5%.
Hospital Inpatient Discharges (SPARCS De-Identified): Pediatric Prevention Quality Indicators (PDI) by Patient Zip Code: Beginning 2009

The dataset contains observed, expected, and risk-adjusted rates for the Agency for Healthcare Research and Quality Pediatric Quality Indicators – Pediatric (AHRQ PDI) beginning in 2009.  The AHRQ PDIs are a set of population based measures that can be used with hospital inpatient discharge data to identify ambulatory care sensitive conditions. These are conditions where 1) the need for hospitalization is potentially preventable with appropriate outpatient care, or 2) conditions that could be less severe if treated early and appropriately. Both the Urinary Tract Infection and Gastroenteritis PDIs include admissions for patients aged 3 months through 17 years.  The asthma PDI includes admissions for patients aged 2 through 17 years.  Eligible admissions for the Diabetes Short-term Complications PDI includes admissions for patients aged 6 through 17 years.

The rates were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data and Claritas population information.  

The observed, expected, risk-adjusted rates, and difference in rates, for each AHRQ PDI are presented by resident zip code (including a statewide total).
2010 State Profile — United States

This state profile includes data from facilities in the United States that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in the United States. In the United States, 13,339 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 1,175,462 clients in substance abuse treatment on March 31, 2010. The survey response rate in the United States was 91.4%.
Patent AT-E400749-T1: [Translated] DRIVE BELT SYSTEM WITH AUTOMATIC BELT TENSION CONTROL

Chemical patent from PubChem database. Patent Number: AT-E400749-T1. Title: Sustained Release Formulation. Filing Date: 1996-08-21. Inventors: Anderson, Robert, Davis, Linda. Abstract: A sustained release formulation is provided, designed to maintain therapeutic drug levels over extended periods, reducing dosing frequency and improvi... IPC Classifications: C07D, A61K, A61P. This patent covers 24 claims related to 6 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Patent AT-E399531-T1: [Translated] USE OF A WATER SOLUBLE FLOCCULATING POLYMER AS AN ANTIPERSPIRANT; COSMETIC PROCESS FOR TREATING SWEAT

Cosmetic composition (I) comprises an anti-perspiring agent comprising a hydrosoluble flocculating polymer, which comprises amine groups carried by a lateral substituent directly connected to the principle chain and does not comprises anti-perspiring salt of zirconium and/or aluminum. An independent claim is also included for an aerosol device comprising a recipient, which comprises deodorant composition; a propellant; and a means of distribution of the aerosol composition.
Supporting Evidence-Based Home Visitation Programs to Prevent Child Abuse and Neglect Project: Colorado Judicial Department

Location:

Denver, Colorado

Home Visiting Program Selected:

Nurse Family Partnership

Home Visiting Target Population:

First-time, low income mothers (ages 15-20 who are fewer than 28 weeks into pregnancy) that are involved with the criminal justice system and have a known history of substance abuse.

Project Overview:
The Denver At-Home Intervention Services Initiative (DAISI) will implement the Nurse Family Partnership (NFP) as a program model for working with pregnant and first-time mothers between the ages of 15-20 years of age who are involved with the juvenile or criminal justice systems and have a history of substance abuse and mental health issues. The goals of the program are to improve prenatal health, help mothers understand child development and foster effective parenting strategies. Denver Juvenile and Family Courts and the Kempe Center will build upon their current, innovative programs to support two existing NFP sites in Denver and create a team-based, community-wide infrastructure that more effectively addresses the needs of the target population. The proposed evaluation includes an implementation analysis and a pre-post analysis of outcomes.

Metadata-only record linking to the original dataset. Open original dataset below.
2010-2012 NSDUH Substate Region Estimates Categorized into Seven Groups by Age Group

This table uses 2010 to 2012 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older by 362 substate regions within the 50 States and the District of Columbia. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). This report presents substate region estimates by age group differences. The scales in this report are a companion piece to the 2010-2012 National Surveys on Drug Use and Health: Substate Age Group Tables.
Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists

Background
          The Hedgehog (Hh) signaling pathway is vital to animal development as it mediates the differentiation of multiple cell types during embryogenesis. In adults, Hh signaling can be activated to facilitate tissue maintenance and repair. Moreover, stimulation of the Hh pathway has shown therapeutic efficacy in models of neuropathy. The underlying mechanisms of Hh signal transduction remain obscure, however: little is known about the communication between the pathway suppressor Patched (Ptc), a multipass transmembrane protein that directly binds Hh, and the pathway activator Smoothened (Smo), a protein that is related to G-protein-coupled receptors and is capable of constitutive activation in the absence of Ptc.
        
        
          Results
          We have identified and characterized a synthetic non-peptidyl small molecule, Hh-Ag, that acts as an agonist of the Hh pathway. This Hh agonist promotes cell-type-specific proliferation and concentration-dependent differentiation in vitro, while in utero it rescues aspects of the Hh-signaling defect in Sonic hedgehog-null, but not Smo-null, mouse embryos. Biochemical studies with Hh-Ag, the Hh-signaling antagonist cyclopamine, and a novel Hh-signaling inhibitor Cur61414, reveal that the action of all these compounds is independent of Hh-protein ligand and of the Hh receptor Ptc, as each binds directly to Smo.
        
        
          Conclusions
          Smo can have its activity modulated directly by synthetic small molecules. These studies raise the possibility that Hh signaling may be regulated by endogenous small molecules in vivo and provide potent compounds with which to test the therapeutic value of activating the Hh-signaling pathway in the treatment of traumatic and chronic degenerative conditions.
HCUP Nationwide Emergency Department Database (NEDS) Restricted Access File

The Healthcare Cost and Utilization Project (HCUP) Nationwide Emergency Department Sample (NEDS) is the largest all-payer emergency department (ED) database in the United States. yielding national estimates of hospital-owned ED visits. Unweighted, it contains data from over 30 million ED visits each year. Weighted, it estimates roughly 145 million ED visits nationally.  Developed through a Federal-State-Industry partnership sponsored by the Agency for Healthcare Research and Quality, HCUP data inform decision making at the national, State, and community levels.

Sampled from the HCUP State Inpatient Databases (SID) and State Emergency Department Databases (SEDD), the HCUP NEDS can be used to create national and regional estimates of ED care. The SID contain information on patients initially seen in the ED and subsequently admitted to the same hospital. The SEDD capture information on ED visits that do not result in an admission (i.e., treat-and-release visits and transfers to another hospital). Developed through a Federal-State-Industry partnership sponsored by the Agency for Healthcare Research and Quality, HCUP data inform decision making at the national, State, and community levels. 

The NEDS contain information about geographic characteristics, hospital characteristics, patient characteristics, and the nature of visits (e.g., common reasons for ED visits, including injuries). The NEDS contains clinical and resource use information included in a typical discharge abstract, with safeguards to protect the privacy of individual patients, physicians, and hospitals (as required by data sources). It includes ED charge information for over 85% of patients, regardless of expected payer, including but not limited to Medicare, Medicaid, private insurance, self-pay, or those billed as ‘no charge’. The NEDS excludes data elements that could directly or indirectly identify individuals, hospitals, or states.Restricted access data files are available with a data use agreement and brief online security training.
Patent AT-E401375-T1: [Translated] POLYURETHANE GEL MATERIAL, PRODUCTION PROCESS AND USES

A material obtained from a polyurethane gel containing finely divided phase-change materials is new. <??>Independent claims are included for: <??>(1) A process for preparation of the material by emulsification or dispersion of the phase-change-material (PCM) in at least one polyurethane (PU) liquid component and transfer (sic) of the PU component to a polyurethane gel; and <??>(2) A shoe insole made from the material and having a textile coating .
Valacyclovir

Valacyclovir Hydrochloride is a prescription antiviral medication used to treat infections caused by herpes viruses, such as genital herpes, cold sores, and shingles. It comes in oral tablets (500 mg and 1 g strengths) and works by stopping the virus from multiplying. Manufactured by Mylan Pharmaceuticals Inc. This information was generated using AI and is provided for informational and research purposes only.
Compound 530275: 2-[(2,4,6-Trioxotetrahydro-5(2H)-pyrimidinylidene)methyl]benzoic acid

Chemical compound data from PubChem database. IUPAC Name: 1-[3,4-bis(3-methylbut-2-enyl)-2,3,5-tris(trimethylsilyloxy)cyclopenta-1,4-dien-1-yl]-3-methylbutan-1-one. Molecular Formula: C29H54O4Si3. Molecular Weight: 551.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Staphylococcal peptidoglycans induce arthritis

Staphylococcus aureus is one of the most important pathogens in septic arthritis. To analyse the arthritogenic properties of staphylococcal peptidoglycan (PGN), highly purified PGN from S. aureus was intra-articularly injected into murine joints. The results demonstrate that PGN will trigger arthritis in a dose-dependent manner. A single injection of this compound leads to massive infiltration of predominantly macrophages and polymorphonuclear cells with occasional signs of cartilage and/or bone destruction, lasting for at least 14 days. Further studies showed that this condition is mediated by the combined impact of acquired and innate immune systems. Our results indicate that PGN exerts a central role in joint inflammation triggered by S. aureus.
Patent AT-E400531-T1: [Translated] COUPLING OF A WASTEWATER TREATMENT PLANT WITH A TREATMENT PLANT FOR Flocculating AND FLOTATION OF WATER STREAMS

Chemical patent from PubChem database. Patent Number: AT-E400531-T1. Title: Novel Pharmaceutical Composition. Filing Date: 2010-06-16. Inventors: Yamamoto, Hiroshi, Schmidt, Hans. Abstract: The present invention relates to a novel pharmaceutical composition comprising one or more active pharmaceutical ingredients and pharmaceutically acce... IPC Classifications: A61K, A61P, C07D. This patent covers 18 claims related to 3 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
SHIP Adults who are not overweight or obese 2011-2021

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024

Adults who are not overweight or obese - This indicator shows the percentage of adults who are not overweight or obese. In Maryland in 2015, of adults considered obese, 52% had high blood pressure, 44% had high cholesterol, and 21% had diabetes. Healthy weight can aid in the control of these conditions if they develop. <a href="https://health.maryland.gov/pophealth/Documents/SHIP/SHIP%20Lite%20Data%20Details/Adults%20who%20are%20Not%20Overweight%20or%20Obese.pdf" > Link to Data Details </a>
Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings and Detailed Tables

This page presents the annual national findings report and detailed tables from the 2010 National Survey on Drug Use and Health (NSDUH). The annual national findings report and the detailed tables include national estimates of rates of initiation and use of illicit drugs (e.g., marijuana, cocaine, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, and sedatives), alcohol, and tobacco products and rates of driving under the influence of drugs or alcohol. The the annual national findings report and detailed tables also covers substance use treatment need/receipt and youth risk and prevention measures. Results are provided for age group, gender, pregnancy status, race/ethnicity, education level, employment status, geographic area, parole/probation status. Comparisons are made between 2010 and 2002 to 2009.
Compound 526850: Acetic acid 3,5-dimethoxy-tetrahydro-pyran-4-yl ester

Chemical compound data from PubChem database. IUPAC Name: (3,5-dimethoxyoxan-4-yl) acetate. Molecular Formula: C9H16O5. Molecular Weight: 204.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
MD COVID-19 - Number of Deaths by Affected Congregate Facility

<b>Summary</b>
<b>This layer has been DEPRECATED</b> (last updated 11/17/2022). This was formerly a weekly update.

The Outbreak-Associated Cases in Congregate Living data dashboard on coronavirus.maryland.gov was redesigned on 11/17/21 to align with other outbreak reporting. Visit https://opendata.maryland.gov/dataset/MD-COVID-19-Congregate-Outbreak/ey5n-qn5s to view Outbreak-Associated Cases in Congregate Living data as reported after 11/17/21.

Deaths at Maryland facilities where at least one confirmed case of COVID-19 is present for the reporting period.

<b>Description</b>
The MD COVID-19 - Number of Deaths by Affected Congregate Facility data layer is a collection of the number of deaths in nursing homes, assisted living facilities, group homes of 10 or more and state and local facilities where at least one positive COVID-19 test result has been reported for the reporting period. Data are reported to MDH by local health departments, the Department of Public Safety and Correctional Services and the Department of Juvenile Services. To appear on the list, facilities report at least one confirmed case of COVID-19 over the prior 14 days. Facilities are removed from the list when health officials determine 14 days have passed with no new cases and no tests pending. The list provides a point-in-time picture of COVID-19 case activity among these facilities. Numbers reported for each facility listed reflect totals ever reported for deaths. Data are updated once weekly.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Patent AT-E401222-T1: [Translated] DEVICE FOR CONTROLLING PRESSURE FLUID

Upgrading existing aircraft braking systems to accommodate replacement of existing brake units employing sintered friction materials with brake units employing carbon-carbon composite friction materials is often desirable. However, when upgrading the braking systems it is necessary to ensure that the integrity of the existing airframe is not compromised by the use of the new brake assemblies employing the carbon-carbon composite friction materials. Consequently, the present invention replaces existing pressure control valves of existing braking systems with an electronic control unit (126) coupled to a pressure control servovalve (128), thereby ensuring proper application of hydraulic pressure to brake assemblies (122). An advantage of this invention is that the pressure profile of the hydraulic fluid is controllable and hence the integrity of the airframe is maintained.
Compound 530405: Norpropoxypheneamide

Chemical compound data from PubChem database. IUPAC Name: [1-[formyl(methyl)amino]-2,3-diphenylpropan-2-yl] propanoate. Molecular Formula: C20H23NO3. Molecular Weight: 325.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526921: Adamantyl-1-methyl-p-methoxyphenyl ketone

Chemical compound data from PubChem database. IUPAC Name: 2-(1-adamantyl)-1-(4-methoxyphenyl)ethanone. Molecular Formula: C19H24O2. Molecular Weight: 284.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
M-9: Comparing and Evaluating Youth Substance Use Estimates from the NSDUH and Other Surveys

This report compares estimates of youth substance use from the 2002 to 2008 National Survey on Drug Use and Health (NSDUH) with estimates of similar measures from Monitoring the Future (MTF) and the Youth Risk Behavior Survey (YRBS). Substances covered include cigarettes, alcohol, marijuana, cocaine, heroin, ecstasy, and inhalants. Results are shown by grade level, in school/dropout status, month of data collection, and the impact of school absenteeism.
Quality Assurance Reporting Requirements (QARR) Health Disparities 2020

This dataset includes Medicaid Managed Care, Commercial HMO, and Commercial PPO performance data from the Quality Assurance Reporting Requirements (QARR) by member demographic characteristics. QARR is largely based on measures of quality developed and published by the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS®). Plans are required to submit quality performance data each year. Demographic information analyzed in this report includes members’ sex, age, race/ethnicity, Medicaid aid category, cash assistance status, behavioral health conditions including serious mental illness (SMI) and substance use disorder (SUD), payer status, and region of residence. Measuring the quality of care, and the ability to measure disparities in care is an important first step to a better understanding of the underlying factors that drive differences in care among certain populations within Medicaid Managed Care, Commercial HMO, and Commercial PPO.

These data are published annually for Medicaid Managed Care in the Health Care Disparities in New York State Report and on the NYSDOH website: http://www.health.ny.gov/health_care/managed_care/reports/